AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00434330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide
Description: Tiered peginesatide starting doses of 0.04 mg/kg or 0.075 mg/kg for participants with an epoetin (alfa or beta) dose of ≤100 Units/kg/week or 100 to 150 Units/kg/week, respectively. Doses were administered intravenously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
Study NCT02697812 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: slow sternal retraction
Description: the sternal retraction (which always need to be performed for coronary artery bypass graft surgery) will be achieved over 15 min instead of the usual 30 sec
Study NCT00875251 — intervention group
Intervention type: DEVICE
Intervention: body composition
Description: Measurements of body composition using 2 differents devices: Bioimpedance measurements will be made with the RJL System (Quantum BIA 101Q equipment) air-displacement plethysmography in the PEA POD System (Life Measurement).
Study NCT02686138 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01962207 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal vaccine GSK134612
Description: One dose administered intramuscularly (IM) in the deltoid of the non-dominant arm
Study NCT02632474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir(TDF)+Lamivudine(3TC)+Efavirenz(EFV)
Description: The first 2 weeks, TDF (300 mg) + 3-TC (300 mg) + EFV (400 mg); week 3, TDF (200 mg) + 3-TC (300 mg) + EFV (400 mg ); week 4, TDF (150 mg) + 3-TC (300 mg) + EFV (400 mg).From week5, if the HIV viral load decreased as expected or no rebound, use TDF (200 mg) + 3-TC (300 mg) + EFV (400 mg) until study complete; if the viral load increases, switch to the standard treatment regimen: TDF (300 mg) + 3-TC (300 mg) + EFV (600 mg).
Study NCT04432857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AN0025
Description: oral administration
Study NCT02733380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: 30mg , Oral twice a week(with an interval of no less than 3 days,;e.g. Monday and Thursday，Tuesday and Friday) until disease progression or unacceptable toxicity develops
Study NCT04432857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Infusion
Study NCT01082406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: catridecacog
Description: Single dose of 35 IU/kg body weight recombinant factor XIII (catridecacog) (Novo Nordisk) administered iv (into the vein) followed by a single dose of 35 IU/kg body weight recombinant factor XIII (Avecia) administered iv.
Study NCT01082406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant factor XIII
Description: Single dose of 35 IU/kg body weight recombinant factor XIII (Avecia) to be administered iv (into the vein) followed by a single dose of 35 IU/kg body weight recombinant factor XIII (catridecacog) (Novo Nordisk) administered iv.
Study NCT02733380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: 20mg/m2， IV on day 1 of each 14 day cycle until disease progression or unacceptable toxicity develops, up to 12 cycles
Study NCT02733380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Doxorubicin or mitoxantrone
Description: 20mg/m2, IV on day 1 of each 14 day cycle（Note：for patients who can not afford the liposomal doxorubicin，may be replaced into mitoxantrone 8mg/m2, IV on day1 of each 14 day cycle） until disease progression or unacceptable toxicity develops, up to 12 cycles
Study NCT03739866 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously in the abdomen
Study NCT03739866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: 50/200/25 mg tablets administered orally once daily
Study NCT02819843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TALIMOGENE LAHERPAREPVEC (TVEC)
Study NCT02819843 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiotherapy
Study NCT02733380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 10mg/m2 , IV on day 1-5 of each 14 day cycle until disease progression or unacceptable toxicity develops, up to 12 cycles
Study NCT02733380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 100mg,Oral at night on each day until disease progression or unacceptable toxicity develops, up to 24 weeks
Study NCT04055038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-Based Drug
Description: Reintroduction of platinum-based chemotherapy
Study NCT04055038 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional chemotherapy
Description: Conventional chemotherapy
Study NCT04859530 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AVC test
Description: The AVC test will be performed during VIA by local midwives: 120 second videos focused on the cervix will be taken right after the application of acetic acid on the cervix. The recording smartphone will be fixed on a tripod situated 15cm away from the cervix.
Study NCT03097848 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RFA
Description: for eligible cases, radiofrequency ablation will be given only.
Study NCT03097848 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RFA
Description: for eligible cases, radiofrequency ablation will be given only.
Study NCT03097848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: for eligible cases, combination treatment with RFA and Sorafenib will be given.That is sorafenib for 2 week,then radiofrequency ablation
Study NCT04283214 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary Resuscitation
Description: Cardiopulmonary Resuscitation based on 2015 American Heart Association guidelines with and without protective equipment on traditional and endomorphic manikins
Study NCT04283214 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiopulmonary Resuscitation
Description: Cardiopulmonary Resuscitation based on 2015 American Heart Association guidelines with and without protective equipment on traditional and endomorphic manikins
Study NCT00765037 — intervention group
Intervention type: DEVICE
Intervention: Encore Reverse Shoulder Prosthesis
Description: rotator cuff deficiency and glenohumeral arthritis
Study NCT02315807 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Study NCT02315807 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Study NCT01258465 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pivotal Response Training
Description: Naturalistic behavioral protocol designed to teach vocal communication.
Study NCT01258465 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Picture Exchange Communication System
Description: Pictorially-based behavioral protocol designed to teach communication to nonverbal children via pictures icons.
Study NCT00920387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mcg LSD
Description: Administering 200 mcg LSD orally once at the start of each of two day-long psychotherapy session
Study NCT00920387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20 mcg LSD
Description: Administer 20 mcg LSD orally once at the start of each of two day-long psychotherapy session
Study NCT00920387 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapy
Description: Therapy provided by male and female co-therapists
Study NCT00920387 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy
Description: Therapy provided by male and female co-therapists
Study NCT01278121 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Diet A
Description: 3 days, 6 meals a day
Study NCT01747863 — intervention group
Intervention type: OTHER
Intervention: Neurologic examination
Description: Neurologic examination includes: (1) neurologic examination using modify Sarnat score at \</= 6 hrs of age, 24 hrs and at discharge home, (2) aEEG at 6 ± 3 hrs of age, (3) Brain MRI before discharge home to 30 days of age.
Study NCT01278121 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Diet B
Description: 10 days, 6 meals a day
Study NCT04282096 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: native and non native casein
Description: selected participant will test the 3 treatments in a random order
Study NCT04282096 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: native and non native casein
Description: selected participant will test the 3 treatments in a random order
Study NCT01900132 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EIM testing
Description: EIM device is placed on the muscle and a high frequency current is delivered to the skin.
Study NCT01900132 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nerve &amp; muscle ultrasonography
Description: Ultrasound waves to examine the muscles and nerves
Study NCT01900132 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nerve conduction studies
Description: Small metal disk electrodes attached to wires onto skin to measure how fast nerves conduct electrical impulses and the strength of the connection between nerves and muscles.
Study NCT01900132 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electromyography (EMG)
Description: Thin needle placed into muscles to record electrical activity-adults only
Study NCT02033057 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscular electrostimulation and percutaneus muscular biopsy.
Description: Muscular electrostimulation everyday and percutaneus muscular biopsy weekly.
Study NCT01504815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatinum
Description: i.v. 100 mg/m2 on days 1, 22 and 43 of radiotherapy
Study NCT01504815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatinum
Description: i.v. 100 mg/m2 on days 1, 22 and 43 of radiotherapy
Study NCT01504815 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional radiotherapy
Description: conventional radiotherapy, 70Gy in 7 weeks
Study NCT01504815 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adaptive radiotherapy
Description: adaptive high dose radiotherapy up to 84 Gy max on 50% uptake GTV in 7 weeks
Study NCT03426163 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Application of knee MRI transformed virtual reality system
Study NCT00168818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: daily dose 150 mg once daily, half a dose on the day of surgery
Study NCT03739866 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: B/F/TAF
Description: 50/200/25 mg tablets administered orally once daily
Study NCT03739866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: Tablets administered orally
Study NCT04654624 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SDF
Description: Steps of SDF 38% application were carried out following the manufacturer's instructions. Eligible primary carious teeth were first dried and isolated using cotton rolls and gauze. Adjacent soft tissues were isolated using petrolleum gelly in order to prevent any irritation or staining from SDF that was directly placed into the carious lesion using a microbrush, allowed to absorb for 2 minutes, then dried with air. Parents were instructed that children should not eat for one hour after treatment. The second application was done after 6 months.
Study NCT04654624 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ART
Description: Steps of ART caries removal were carried out following the Frencken et al. criteria where the cavity opening was widened using the tip of a dental hatchet. The carious dentin was then removed using a spoon excavator starting at the enamel-dentin junction, unsupported enamel was removed using the hatchet, and finally the cavity was cleaned using a wet cotton pellet and dried. After complete removal of infected dentin, the cavity walls and floor were conditioned for 10 seconds, washed and dried with cotton pellets, then restored with chemically cured glass ionomer cement that was applied under finger pressure, then coated with petroleum jelly.
Study NCT00918164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04457845
Description: Single dose, 8 mg as oral tablet and solution formulation
Study NCT04044599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gynoflor
Description: VAGİNAL GYNOFLOR
Study NCT00168818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enoxaparin
Description: 40 mg once daily
Study NCT01422629 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonic ablation device
Description: High Intensity focused ultrasound treatment
Study NCT03462979 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immunochromatographic lateral flow test
Description: The immunochromatographic lateral flow test (Gluten Detective) is an at-home test that detects gluten immunogenic peptides excreted in stool or urine. This test can detect gluten exposures which occurred either during the last 24 hours (urine) or within up to a 7 day window (stool). Minimum intake amounts of gluten for successful detection using these test are 50mg (stool) to 500mg (urine)
Study NCT00625053 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic repair
Description: Complete adhesiolysis between viscera and abdominal wall, complete dissection of round ligament and subumbilical fatty tissue to expose the posterior fascia at least 5 cm further than the cranial and caudal limits of the fascial defect or the original incision. Overlap of minimum 5 cm is calculated and mesh inserted in the abdominal cavity through 12mm optical trocar. Fixation of a antiadhesive composite mesh with helicoidal pins with maximum 15mm interval, double crown technique. No pressure decrease maneuver is done during mesh fixation or at another time during the operation. No transparietal suture fixation. No fascial closure.
Study NCT00625053 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open midline incisional hernia repair
Description: * Underlay retromuscular repair: Medial border of the anterior fascia opened, posterior aspect of rectus muscle dissected to reach lateral border of rectus sheet, bilaterally. Peritoneum and posterior rectus fascia closed with absorbable running suture. Polyester or light-weight polypropylene mesh is cut to fit the reconstructed area, to have 3cm overlap on caudal and cranial defect limits. Mesh is fixed by absorbable sutures. Anterior fascia is closed with absorbable running suture. Components separation upon need.~* Intraperitoneal onlay repair: Mesh is inserted intraperitoneally and fixed by a complete running suture (optional fixation with helicoidal pins or stapler). Fascial defect is closed with interrupted or running absorbable suture. Components separation upon need.
Study NCT02916667 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dietary guidelines
Description: dietary guidelines will include chrono- nutrition diet plan
Study NCT02916667 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: dietary guidelines
Description: dietary guidelines will include chrono- nutrition diet plan
Study NCT03712943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib orally 80 mg daily for 21 days (3 weeks on, 1 week off).
Study NCT03712943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240 mg administered intravenously every 2 weeks.
Study NCT03452839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Meropenem or injection vials to be re-constituted in a solution of NaCl 0.9%.
Study NCT03452839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem
Description: Meropenem or injection vials to be re-constituted in a solution of NaCl 0.9%.
Study NCT04028193 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Calogen
Description: Polyunsaturated liquid fat supplement
Study NCT04028193 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Resource Energy
Description: Carbohydrate Supplement
Study NCT03980574 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: R Drink
Description: R Drink is a dietary supplement drink containing filtered reverse osmosis water and 150 mg/L of both USP Grade calcium chloride and magnesium chloride, 10 mg/L Biotin (vitamin B7), 500 mg/L of Niacinamide (B3) and 550 mg/L of Choline.
Study NCT02218801 — intervention group
Intervention type: OTHER
Intervention: Evaluation of treatment for liver metastasis
Study NCT02193334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KP-100IT
Study NCT02193334 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01218750 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Triple therapy for diffuse diabetic macular edema
Description: Three port pars plana vitrectomy is performed by one surgeon (JR). Induction of PVD is initiated by active suction with the vitrectomy probe over the ONH and continued peripherally. Peeling of the epimacular tissue and ILM is performed by grasping the flap of the ILM with an eckhardts forceps. Trypan Blue is used to stain the ILM. Peripheral laser endophotocoagulation is performed in cases of avascular areas based on FA, active neovascularization, peripheral retinoschisis or retinal breaks. All eyes have a 1,25 mg/0,05 ml bevacizumab injection into vitreous cavity and SF6 gas tamponade at the end of the procedure. Even of absence of cataract formation, a combined procedure is performed because of exactly peripheral vitreous shaving and prevention of cataract formation.
Study NCT03900130 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Preload
Description: In the 2 x 2 factorial design we vary two factors:~1. caloric load of the preload such that it is either high calorie or low.~2. protein to carbohydrate ratio of the preload such that it is either high or low
Study NCT03317158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab (Cohort 1-3)
Description: Durvalumab 1120 mg intravenously Day 1 every 21 days x 8 cycles.
Study NCT03317158 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiotherapy (EBRT)
Description: EBRT 6 Gy x 3; Cycle 1 Day 1, 3, and 5
Study NCT03317158 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guérin (BCG)
Description: Dose level 0 (starting dose) = Full-dose~Dose level-1 = 1/3rd-dose BCG. Dose level -1 is expected to be utilized during the phase II portion of the study due to the ongoing and persistent shortage of BCG in the US.
Study NCT03317158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg intravesical weekly (+/- 2 days) x 6 doses
Study NCT03317158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 37.5 mg intravesical weekly (+/- 2 days) x 6 doses.
Study NCT00283803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exisulind
Description: Oral antineoplastic agent that induces apoptosis in cancerous cells.
Study NCT03317158 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab 75 mg intravenously Day 1 (+/- 2 days) every 28 days x 4 cycles.
Study NCT03270878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib Oral Tablet
Description: Subjects will receive a single 100 mg oral tablet of glasdegib under fasted conditions, either in study period 1 or 2, depending on randomization.
Study NCT03317158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab (Cohort 4/5)
Description: Durvalumab 1500 mg intravenously Day 1 (+/- 2 days) every 28 days x 6 cycles.
Study NCT03270878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glasdegib IV infusion
Description: Subjects will receive a 50 mg IV infusion of glasdegib over approximately 1.25 hours, in the fasted state, in either period 1 or 2 based on randomization.
Study NCT00387556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: ondansetron (0.15 mg/kg/dose; maximum dose 4 mg)
Study NCT00387556 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron
Description: ondansetron (0.15 mg/kg/dose; maximum dose 4 mg)
Study NCT03317158 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: To be determined
Description: Other regimens to be determined
Study NCT02421380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Pyruvate
Study NCT00283803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: luteinizing hormone-releasing hormone (LHRH) agonist
Description: Hormonal therapy to suppress testosterone as a standard treatment for Prostate Cancer.
Study NCT00283803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiandrogen
Description: Hormonal therapy used as lead in treatment with luteinizing hormone-releasing hormone (LHRH) agonist to prevent the initial rise in testosterone (testosterone flare) seen during the first dose of LHRH agonists.